Figure 3.
Inhibition of human adrenocortical cell proliferation by IsoQ compound nos. 31 and 32. A and B, H295R TR/SF-1 cells were treated with increasing doses of the no. 31 (A) and 32 compounds (both at doses ranging from 10−8 to 10−5 m; B) in duplicate wells in the absence or presence of Dox (1 μg/ml). Data are expressed as the percentage of increment or reduction over the number of cells cultured in the presence of DMSO vehicle for 4 d (mean ± sem of four experiments). The difference in cell numbers between H295R TR/SF-1 cells cultured in the absence or presence of Dox is statistically significant (+; P < 0.01, t test). *, Values significantly different from DMSO control (P < 0.01, two way-ANOVA with Bonferroni posttest). C and D, Effect of the no. 31 (C) and 32 (D) compounds (both at doses ranging from 10−8 to 10−5 m) on proliferation of SW-13 cells. Data are expressed as the percentage of increment or reduction over the number of cells cultured in the presence of DMSO vehicle for 4 d (mean ± sem of four experiments).